(TRVI) Trevi Therapeutics - Ratings and Ratios
Chronic Cough, Nalbuphine Formulation, Pruritus Therapy
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 73.5% |
| Value at Risk 5%th | 107% |
| Relative Tail Risk | -11.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.21 |
| Alpha | 369.82 |
| CAGR/Max DD | 1.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.370 |
| Beta | 0.241 |
| Beta Downside | 0.249 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.04% |
| Mean DD | 21.95% |
| Median DD | 18.47% |
Description: TRVI Trevi Therapeutics November 18, 2025
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharma focused on oral, extended-release nalbuphine formulations to treat chronic cough in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, as well as refractory cough and pruritic skin conditions.
The lead asset, Haduvio (nalbuphine ER), is currently in a Phase 2b trial evaluating cough reduction in IPF patients, a Phase 2 study for chronic pruritus, and a combined Phase 2b/3 program for prurigo nodularis. The company holds an exclusive license with Endo Pharmaceuticals to develop and commercialize nalbuphine-based products across multiple formulations.
Founded in 2011 and headquartered in New Haven, Connecticut, Trevi operates under the GICS sub-industry “Pharmaceuticals” and trades as common stock on the NASDAQ.
Key external metrics: as of the latest 10-Q, Trevi reported a cash runway of roughly 12 months, a market capitalization near $150 million, and a burn rate of $15 million per quarter. The IPF therapeutic market is projected to exceed $2 billion by 2028, driven by an aging population and limited existing cough-specific treatments, which could provide a sizable addressable market for an effective oral therapy.
For a deeper dive into valuation assumptions and comparable peer analysis, you may find ValueRay’s detailed model worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-45.9m TTM) > 0 and > 6% of Revenue (6% = 8760 TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 28.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 129.6k% (prev 33.1k%; Δ 96.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -44.0m > Net Income -45.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 21.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (145.1m) change vs 12m ago 43.61% (target <= -2.0% for YES) |
| Gross Margin 22.60% (prev 18.18%; Δ 4.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.11% (prev 0.26%; Δ -0.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -45.9k (EBITDA TTM -45.7m / Interest Expense TTM 1000 ) >= 6 (WARN >= 3) |
Altman Z'' -36.59
| (A) 0.95 = (Total Current Assets 198.3m - Total Current Liabilities 9.04m) / Total Assets 199.4m |
| (B) -1.61 = Retained Earnings (Balance) -321.5m / Total Assets 199.4m |
| warn (B) unusual magnitude: -1.61 — check mapping/units |
| (C) -0.34 = EBIT TTM -45.9m / Avg Total Assets 134.1m |
| (D) -33.58 = Book Value of Equity -321.3m / Total Liabilities 9.57m |
| Total Rating: -36.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.57
| 1. Piotroski 1.0pt |
| 2. FCF Yield -2.87% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 1.23 |
| 6. ROIC - WACC (= -38.11)% |
| 7. RoE -31.23% |
| 8. Rev. Trend 18.89% |
| 9. EPS Trend 53.15% |
What is the price of TRVI shares?
Over the past week, the price has changed by -5.20%, over one month by +7.76%, over three months by +54.79% and over the past year by +254.72%.
Is TRVI a buy, sell or hold?
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 64.4% |
| Analysts Target Price | 21 | 64.4% |
| ValueRay Target Price | 19.2 | 50.7% |
TRVI Fundamental Data Overview December 06, 2025
P/B = 9.0199
Beta = 0.84
Revenue TTM = 146.0k USD
EBIT TTM = -45.9m USD
EBITDA TTM = -45.7m USD
Long Term Debt = 823.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 296.0k USD (from shortTermDebt, last quarter)
Debt = 823.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -56.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.53b USD (1.73b + Debt 823.0k - CCE 194.9m)
Interest Coverage Ratio = -45.9k (Ebit TTM -45.9m / Interest Expense TTM 1000 )
FCF Yield = -2.87% (FCF TTM -44.0m / Enterprise Value 1.53b)
FCF Margin = -30.2k% (FCF TTM -44.0m / Revenue TTM 146.0k)
Net Margin = -31.4k% (Net Income TTM -45.9m / Revenue TTM 146.0k)
Gross Margin = 22.60% ((Revenue TTM 146.0k - Cost of Revenue TTM 113.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.69 (Enterprise Value 1.53b / Total Assets 199.4m)
Interest Expense / Debt = 0.12% (Interest Expense 1000 / Debt 823.0k)
Taxrate = 0.13% (-15.0k / -11.8m)
NOPAT = -45.8m (EBIT -45.9m * (1 - 0.13%)) [loss with tax shield]
Current Ratio = 21.93 (Total Current Assets 198.3m / Total Current Liabilities 9.04m)
Debt / Equity = 0.00 (Debt 823.0k / totalStockholderEquity, last quarter 189.8m)
Debt / EBITDA = 1.23 (negative EBITDA) (Net Debt -56.0m / EBITDA -45.7m)
Debt / FCF = 1.27 (negative FCF - burning cash) (Net Debt -56.0m / FCF TTM -44.0m)
Total Stockholder Equity = 146.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.00% (Net Income -45.9m / Total Assets 199.4m)
RoE = -31.23% (Net Income TTM -45.9m / Total Stockholder Equity 146.8m)
RoCE = -31.08% (EBIT -45.9m / Capital Employed (Equity 146.8m + L.T.Debt 823.0k))
RoIC = -31.21% (negative operating profit) (NOPAT -45.8m / Invested Capital 146.8m)
WACC = 6.90% (E(1.73b)/V(1.73b) * Re(6.90%) + D(823.0k)/V(1.73b) * Rd(0.12%) * (1-Tc(0.00)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 20.77%
Fair Price DCF = unknown (Cash Flow -44.0m)
EPS Correlation: 53.15 | EPS CAGR: 125.2% | SUE: 1.72 | # QB: 2
Revenue Correlation: 18.89 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.13 | Chg30d=-0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.48 | Chg30d=+0.011 | Revisions Net=+4 | Growth EPS=-28.1% | Growth Revenue=+0.0%
Additional Sources for TRVI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle